CRISPR patent dispute may finally be resolved

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. 

Who owns the biggest biotech advance of the century? Geneticists in Boston may have found a way around a high-stakes patent dispute over one of the most significant biotechnology breakthroughs in recent years, a gene-editing tool called CRISPR.

CRISPR is faster, easier and cheaper than other gene editing techniques. It works in nearly everyone’s hands, democratising the pursuit of tweaking genes, which can be used for everything from breeding better plants to developing treatments for leukemia or HIV infections.

But the technology is embroiled in a patent dispute between researchers in California and Massachusetts.

Researchers Jennifer Doudna at the University of California in Berkeley and Emmanuelle Charpentier at the Max Planck Institute for Infection Biology in Berlin, Germany, filed the first patent on CRISPR, dated December 2012. But it was Feng Zhang at the Broad Institute of MIT and Harvard who was granted the patent, although he filed in October 2013. Zhang and the Broad Institute paid to expedite their patent and were the first to show that the tool works in human cells.

Now, Zhang has announced a potential way to resolve the dispute: his team has identified two novel DNA-slicing enzymes that aren’t covered by any of the previous patents and that can replace the one at the centre of the legal spat. Zhang’s team has used the enzymes to successfully edit human genomes. The discovery could potentially sidestep the patent dispute: it offers a different way to perform CRISPR gene editing.

Read full, original post: DNA-cutting enzymes could slice through gene editing patent spat

 

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Nurturing Care Beneath the Crunchy Moms Logo
Crunchy Moms disinformation flood: Zuckerberg's Facebook has opened floodgates on measles and vaccines
Screenshot-2026-11-19-at-7.54.57-PM
European General Court sides with scientists, dismisses activist claims that glyphosate is toxically dangerous
Screenshot-2026-11-16-at-2.37.32-PM
30 years of GMO farming: Is the boom in glyphosate and glufosinate use harming the environment? Data show they’re the most sustainable choice
Soybean Harvest in Cupped Hands
30 years of GMO farming: Defying cynics, we’ve had larger harvests, lower costs, and $385 billion in added global farmer income
Stormlit Portrait Over Golden Mountains
Searching for life where no one thought to look: A renowned astrophysicist’s seemingly quixotic quest to explore Venus’s clouds
gut health
Health vs. hype on gut health: We are flooded by misinformation
Screenshot-2026-11-17-at-12.18.09-PM
Challenging glyphosate fear-mongering: Statewide Nebraska study finds no link between weedkiller use and non-Hodgkin lymphoma
Screenshot-2026-11-19-at-7.23.23-PM
Viewpoint: After a yearlong hiatus, the U.S. Preventive Services Task Force is back in business—gutted by RFK Jr. and promoting junk science
Screenshot-2026-11-18-at-2.44.24-PM
Why should thousands of Americans die every year waiting for a kidney transplant? There’s an easy fix to this morbid reality
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.